London’s international investment does not only take the form of funding of construction or the purchase of skyscrapers by Middle Eastern or Asian wealth funds. The capital also continues to see new offices opening as companies based elsewhere in the world expand into the UK market by way of a bricks-and-mortar office or in order to boost their UK presence by increasing their office space. 

One such company is the pharmaceutical research and consultancy company, Evidera. It is a subsidiary of Symphony Technology Group, the technology and services-focused private equity firm, which acquired Evidera –itself formed from elements of the United BioSource Corporation – last September. Evidera describes itself as an industry-leading business, and its roles involve assisting pharmaceutical companies in marketing their products and targeting their client base by using epidemiology, research, and health economics analysis. Evidera offers to its clients analysis of the effectiveness and value of treatments, and it claims a worldwide reach achieved through its partnerships with life sciences organisations across the globe. 

Its other offices are located in Lexington, Massachusetts, San Francisco, Seattle in Washington state, and Montreal and it has a European office in Budapest, while its headquarters are in Bethesda, Maryland. 

Evidera’s two previous sites in London have been replaced by a west London offices in Hammersmith, where at least 100 employees will be based and which provides scope for future growth. It is hoped that the working environment will attract the best experts in the field to the company. The company has taken just over 11,400 square feet of space overlooking Hammersmith roundabout, a location that also is home to other multinationals such as Coca-Cola and L’Oreal. 

This news was brought to you by Morgan Pryce, a specialist tenant acquisition agent with offices in Oxford Circus and the City. Morgan Pryce specialises in search, negotiation and project management and works exclusively for tenants.